Factor Xa Inhibitor-Related Intracranial Hemorrhage (FiX-ICH): Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.

Conclusions: Administration of PCC after apixaban and rivaroxaban-related ICH provided a high rate of excellent or good hemostasis (81.8%) coupled with a 3.8% thrombosis rate. Randomized, controlled trials evaluating the clinical efficacy of PCC in patients with FXa inhibitor-related ICH are needed. PMID: 32264698 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32264698?dopt=Abstract

Source: Circulation - April 7, 2020 Category: Cardiology Authors: Panos NG, Cook AM, John S, Jones GM, Neurocritical Care Society (NCS) Pharmacy Study Group Tags: Circulation Source Type: research